Weiss Ratings started coverage on shares of iBio (NASDAQ:IBIO – Free Report) in a report published on Wednesday morning,Weiss Ratings reports. The brokerage issued a sell (e+) rating on the stock.
Separately, Wall Street Zen raised shares of iBio from a “sell” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
Read Our Latest Stock Report on iBio
iBio Stock Performance
iBio Company Profile
iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than iBio
- Market Cap Calculator: How to Calculate Market Cap
- This AI Chip Giant Could Be the Market’s Next Big Winner
- How to Profit From Value Investing
- Broadcom Inks OpenAI Deal: Why It’s A Huge Win for AVGO Stock
- What is the MACD Indicator and How to Use it in Your Trading
- Institutions Are Fueling CrowdStrike’s Next Leg Higher
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
